Featured News

Latiglutenase is a dual enzyme investigational product designed to break down gluten in the stomach. Learn more about the trial and what this means for celiac disease patients.

Ukko, a startup focused on eradicating food allergies, intolerances, and sensitivities, has reached a promising stage in its effort to develop a gluten specifically designed for people with celiac disease.

We are determined to use every resource at our disposal, including strategic funding of research and advocacy, to help discover and bring to the celiac disease patient community therapeutic alternatives to the gluten-free diet.

The Celiac Disease Foundation is proud to announce its sponsorship of the April 17th University of Chicago’s Celiac Disease & The Continuum of Care Virtual CME Symposium.

The Celiac Disease Foundation recently published an article in Mediaplanet’s Autoimmune Diseases digital campaign.

The Celiac Disease Foundation is proud to have been involved by recruiting patients essential for this trial’s success.

Anokion SA announced that they have initiated patient dosing in the multiple ascending dose (MAD) portion of its ACeD study.

The Celiac Disease in Learning Environments: A Continuing Education Program for Nurses Who Care for Children with Celiac Disease training seminar will complement the recommendations found in the 2020 Voluntary Recommendations for Managing Celiac Disease in Learning Environments.

The Celiac Disease Genomic Environmental Microbiome and Metabolomic (CDGEMM) study is revealing how genetic and lifestyle factors make children susceptible to autoimmune diseases such as celiac disease, inflammatory bowel disease, and multiple sclerosis.

Thank you to Schär for sponsoring our upcoming Patient Education and Advocacy Summit. For over 35 years, Schär has been dedicated to the celiac and gluten-sensitive communities by providing a safe, flavorful, and quality line of gluten-free products. Learn more about Schär’s collection of gluten-free goods.